TransMedics Reports Fourth Quarter and Full Year 2025 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for TMDX
Across the 11 sessions after earlier TMDX headlines, the stock closed higher 6 times and lower 5 times, with a median move of 1.8% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | TMDX | SPY |
|---|---|---|---|
| Feb 23, 2026 | TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | +0.3% | -1.0% |
| Feb 18, 2026 | TransMedics to Present at Upcoming March Investor Conferences | +1.3% | +0.5% |
| Feb 11, 2026 | TransMedics to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026 | -4.3% | -0.0% |
| Feb 9, 2026 | TransMedics Receives Full and Unconditional FDA IDE Approval for Next-Generation OCS Heart ENHANCE Trial | +0.9% | +0.5% |
| Jan 12, 2026 | TransMedics Announces New Global Headquarters and Expansion at Assembly Innovation Park in Somerville, Massachusetts | -1.8% | +0.2% |
| Dec 31, 2025 | TransMedics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | -0.2% | -0.7% |
Quantisnow market dataNASDAQ
TMDX
TransMedics Group Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Listed since
- 2019
Get push alerts for TMDX
Full TMDX profile on Quantisnow Follow TMDX and get a push notification the moment its next story breaks.